University of Hertfordshire

View graph of relations
Original languageEnglish
Number of pages5
Pages (from-to)147-51
JournalFuture cardiology
Journal publication date11 Mar 2015
Volume11
Issue2
DOIs
Publication statusPublished - 11 Mar 2015

Abstract

ABSTRACT  Vitamin K antagonists (VKAs) have traditionally been the standard of care for the thromboprophylactic anticoagulation of patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion. X-VeRT was the first prospective trial to explore the safety and efficacy of one of the non-VKA oral anticoagulants, rivaroxaban, compared with dose-adjusted VKA as thromboprophylaxis in patients with NVAF scheduled to undergo cardioversion. The protocol allowed either early (1-5 days) or delayed (3-8 weeks) cardioversion to be performed. Rivaroxaban use (20 mg once daily or 15 mg if creatinine clearance was 30-49 ml/min) was associated with a similar incidence of adverse cardiovascular events and bleeding as VKA use; however, rivaroxaban significantly reduced the time to cardioversion in those undergoing delayed cardioversion. Thus, rivaroxaban is a safe alternative to VKAs for thromboprophylaxis in patients with NVAF undergoing elective cardioversion.

ID: 13239933